SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)

Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and adv...

Descripción completa

Detalles Bibliográficos
Autores: Serrano, Cesar|||0000-0003-1416-8739, Alvarez, Rosa|||0000-0003-0935-8298, Carrasco, Juan Antonio, Marquina, Gloria|||0000-0002-8961-9787, Martínez-García, Jerónimo|||0000-0002-2295-5161, Martínez-Marín, Virginia, Sala, María Ángeles, Sebio, Ana|||0000-0003-3333-2370, Sevilla, Isabel, Martín-Broto, Javier|||0000-0001-7350-6916
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:300806
Acceso en línea:https://ddd.uab.cat/record/300806
https://dx.doi.org/urn:doi:10.1007/s12094-023-03177-7
Access Level:acceso abierto
Palabra clave:Avapritinib
GIST
Imatinib
Ripretinib
id ES_e4ab102e50c39cd266a579f00a155c58
oai_identifier_str oai:ddd.uab.cat:300806
network_acronym_str ES
network_name_str España
repository_id_str
spelling SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)Serrano, Cesar|||0000-0003-1416-8739Alvarez, Rosa|||0000-0003-0935-8298Carrasco, Juan AntonioMarquina, Gloria|||0000-0002-8961-9787Martínez-García, Jerónimo|||0000-0002-2295-5161Martínez-Marín, VirginiaSala, María ÁngelesSebio, Ana|||0000-0003-3333-2370Sevilla, IsabelMartín-Broto, Javier|||0000-0001-7350-6916AvapritinibGISTImatinibRipretinibGastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/300806https://dx.doi.org/urn:doi:10.1007/s12094-023-03177-7reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3008062026-06-06T12:50:31Z
dc.title.none.fl_str_mv SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
title SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
spellingShingle SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
Serrano, Cesar|||0000-0003-1416-8739
Avapritinib
GIST
Imatinib
Ripretinib
title_short SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
title_full SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
title_fullStr SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
title_full_unstemmed SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
title_sort SEOM-GEIS clinical guideline for gastrointestinal stromal tumors (2022)
dc.creator.none.fl_str_mv Serrano, Cesar|||0000-0003-1416-8739
Alvarez, Rosa|||0000-0003-0935-8298
Carrasco, Juan Antonio
Marquina, Gloria|||0000-0002-8961-9787
Martínez-García, Jerónimo|||0000-0002-2295-5161
Martínez-Marín, Virginia
Sala, María Ángeles
Sebio, Ana|||0000-0003-3333-2370
Sevilla, Isabel
Martín-Broto, Javier|||0000-0001-7350-6916
author Serrano, Cesar|||0000-0003-1416-8739
author_facet Serrano, Cesar|||0000-0003-1416-8739
Alvarez, Rosa|||0000-0003-0935-8298
Carrasco, Juan Antonio
Marquina, Gloria|||0000-0002-8961-9787
Martínez-García, Jerónimo|||0000-0002-2295-5161
Martínez-Marín, Virginia
Sala, María Ángeles
Sebio, Ana|||0000-0003-3333-2370
Sevilla, Isabel
Martín-Broto, Javier|||0000-0001-7350-6916
author_role author
author2 Alvarez, Rosa|||0000-0003-0935-8298
Carrasco, Juan Antonio
Marquina, Gloria|||0000-0002-8961-9787
Martínez-García, Jerónimo|||0000-0002-2295-5161
Martínez-Marín, Virginia
Sala, María Ángeles
Sebio, Ana|||0000-0003-3333-2370
Sevilla, Isabel
Martín-Broto, Javier|||0000-0001-7350-6916
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Avapritinib
GIST
Imatinib
Ripretinib
topic Avapritinib
GIST
Imatinib
Ripretinib
description Gastrointestinal stromal tumor (GIST) is the most common malignant neoplasm of mesenchymal origin, and a paradigmatic model for a successful rational development of targeted therapies in cancer. The introduction of tyrosine kinase inhibitors with activity against KIT/PDGFRA in both localized and advanced stages has remarkably improved the survival in a disease formerly deemed resistant to all systemic therapies. These guidelines are elaborated by the conjoint effort of the Spanish Society of Medical Oncology (SEOM) and the Spanish Sarcoma Research Group (GEIS) and provide a multidisciplinary and updated consensus for the diagnosis and treatment of GIST patients. We strongly encourage that the managing of these patients should be performed within multidisciplinary teams in reference centers.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/300806
https://dx.doi.org/urn:doi:10.1007/s12094-023-03177-7
url https://ddd.uab.cat/record/300806
https://dx.doi.org/urn:doi:10.1007/s12094-023-03177-7
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422611974324224
score 15,812429

Similares en LA Referencia